DLRHX Holdings — Nomura Healthcare Fund
All 108 reported holdings of Nomura Healthcare Fund (DLRHX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Ucb SA | 5.19% | $38.96M |
| Abbvie, Inc. | 4.19% | $31.45M |
| Eli Lilly & Company | 4.16% | $31.19M |
| Regeneron Pharmaceuticals, Inc. | 3.91% | $29.31M |
| Unitedhealth Group, Inc. | 3.88% | $29.09M |
| Pfizer, Inc. | 3.84% | $28.78M |
| Merck & Company, Inc. | 3.68% | $27.63M |
| Gilead Sciences, Inc. | 3.54% | $26.53M |
| Astrazeneca PLC | 3.27% | $24.50M |
| Elevance Health, Inc. | 3.25% | $24.36M |
| Roche Holding AG | 3.01% | $22.61M |
| Chugai Pharmaceutical Co. Ltd. | 2.77% | $20.79M |
| Viatris, Inc. | 2.48% | $18.58M |
| Oruka Therapeutics, Inc. | 2.41% | $18.08M |
| Halozyme Therapeutics, Inc. | 2.30% | $17.22M |
| Amgen, Inc. | 2.27% | $17.02M |
| Illumina, Inc. | 2.11% | $15.82M |
| Alkermes PLC | 1.82% | $13.62M |
| Viking Therapeutics, Inc. | 1.72% | $12.88M |
| Vertex Pharmaceuticals, Inc. | 1.66% | $12.42M |
| Roivant Sciences Ltd. | 1.60% | $11.97M |
| Neurocrine Biosciences, Inc. | 1.57% | $11.80M |
| Arcus Biosciences, Inc. | 1.56% | $11.69M |
| Zimmer Biomet Holdings, Inc. | 1.42% | $10.68M |
| Boston Scientific Corp. | 1.42% | $10.67M |
| Sanofi SA | 1.37% | $10.26M |
| Uniqure NV | 1.34% | $10.02M |
| Stryker Corp. | 1.26% | $9.45M |
| Incyte Corp. | 1.21% | $9.07M |
| Alnylam Pharmaceuticals, Inc. | 1.20% | $9.03M |
| Cogent Biosciences, Inc. | 1.19% | $8.90M |
| Federal National Mortgage Association | 1.13% | $8.46M |
| Medtronic PLC | 1.04% | $7.82M |
| Cvs Health Corp. | 1.03% | $7.76M |
| Abbott Laboratories | 0.97% | $7.26M |
| Quest Diagnostics, Inc. | 0.85% | $6.36M |
| Anaptysbio, Inc. | 0.84% | $6.33M |
| Tarsus Pharmaceuticals, Inc. | 0.84% | $6.29M |
| Federal Home Loan Mortgage Corp. | 0.84% | $6.28M |
| Rigel Pharmaceuticals, Inc. | 0.83% | $6.26M |
| Biogen, Inc. | 0.81% | $6.05M |
| Grail, Inc. | 0.77% | $5.80M |
| Biomarin Pharmaceutical, Inc. | 0.76% | $5.72M |
| Vir Biotechnology, Inc. | 0.68% | $5.09M |
| Johnson & Johnson | 0.68% | $5.08M |
| Monte Rosa Therapeutics, Inc. | 0.65% | $4.84M |
| Immunovant, Inc. | 0.63% | $4.70M |
| Abivax SA | 0.53% | $4.00M |
| Syndax Pharmaceuticals, Inc. | 0.52% | $3.93M |
| Madrigal Pharmaceuticals, Inc. | 0.50% | $3.76M |
| Goldman Sachs Trust | 0.49% | $3.67M |
| Morgan Stanley Institutional Liquidity Funds | 0.49% | $3.67M |
| Fidelity Colchester Street Trust | 0.49% | $3.67M |
| Blackrock Liquidity Funds | 0.49% | $3.67M |
| Theravance Biopharma, Inc. | 0.47% | $3.55M |
| Xencor, Inc. | 0.43% | $3.22M |
| Structure Therapeutics, Inc. | 0.41% | $3.11M |
| Perrigo Co PLC | 0.32% | $2.39M |
| Acadia Pharmaceuticals, Inc. | 0.31% | $2.34M |
| Ultragenyx Pharmaceutical, Inc. | 0.31% | $2.34M |
| Compugen Ltd. | 0.29% | $2.18M |
| Moonlake Immunotherapeutics | 0.29% | $2.14M |
| Macrogenics, Inc. | 0.26% | $1.94M |
| First Tracks Biotherapeutics, Inc. | 0.25% | $1.89M |
| Regenxbio, Inc. | 0.24% | $1.79M |
| Biontech SE | 0.22% | $1.67M |
| United Therapeutics Corp. | 0.22% | $1.63M |
| Arvinas, Inc. | 0.20% | $1.50M |
| Moderna, Inc. | 0.19% | $1.40M |
| Cytokinetics, Inc. | 0.17% | $1.28M |
| Coherus Oncology, Inc. | 0.17% | $1.26M |
| Nektar Therapeutics | 0.16% | $1.19M |
| Janux Therapeutics, Inc. | 0.16% | $1.18M |
| Vaxcyte, Inc. | 0.15% | $1.16M |
| Proqr Therapeutics NV | 0.15% | $1.15M |
| Cosmo NV | 0.15% | $1.15M |
| Cellectis SA | 0.09% | $680.62K |
| Olema Pharmaceuticals, Inc. | 0.08% | $625.50K |
| Viridian Therapeutics, Inc. | 0.07% | $539.53K |
| Puma Biotechnology, Inc. | 0.07% | $496.78K |
| Wave Life Sciences Ltd. | 0.06% | $476.16K |
| Organon & Company | 0.05% | $399.43K |
| Instil Bio, Inc. | 0.05% | $384.50K |
| Intellia Therapeutics, Inc. | 0.05% | $338.40K |
| Karyopharm Therapeutics, Inc. | 0.04% | $325.66K |
| Atea Pharmaceuticals, Inc. | 0.04% | $325.50K |
| Allogene Therapeutics, Inc. | 0.04% | $305.30K |
| Altimmune, Inc. | 0.04% | $304.00K |
| Myriad Genetics, Inc. | 0.04% | $285.50K |
| Rocket Pharmaceuticals, Inc. | 0.03% | $198.36K |
| Sarepta Therapeutics, Inc. | 0.03% | $197.67K |
| Amarin Corp. PLC | 0.02% | $151.43K |
| Phio Pharmaceuticals Corp. | 0.01% | $51.25K |
| Mirati Therapeutics, Inc. | 0.01% | $42.00K |
| Landos Biopharma, Inc. | 0.00% | $36.94K |
| Lite Strategy, Inc. | 0.00% | $27.67K |
| Contra Surface Oncolog | 0.00% | $26.95K |
| Innocare Pharma Ltd. | 0.00% | $25.77K |
| Sangamo Therapeutics, Inc. | 0.00% | $21.56K |
| Nextcure, Inc. | 0.00% | $20.00K |
| Fortress Biotech, Inc. | 0.00% | $20.40K |
| Voyager Therapeutics, Inc. | 0.00% | $19.95K |
| Akero Therapeutics Inc | 0.00% | $16.25K |
| Euroapi SA | 0.00% | $13.26K |
| Galmed Pharmaceuticals Ltd. | 0.00% | $946 |
| Ambit Biosciences Corp. Cvr | 0.00% | $0 |
| Mustang Bio, Inc. | 0.00% | $112 |
| Sio Gene Therapies, Inc. | 0.00% | $0 |
DLRHX overview: performance, fees, allocation and SEC filings